Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
This study evaluated the real-world effectiveness of trastuzumab deruxtecan (T-DXd) in patients with breast cancer brain metastases (BCBM), generating data from populations underrepresented in clinical trials. Patients with BCBM treated with T-DXd across seven U.S. health systems from 2019 to 2023 were retrospectively identified. HER2 status was classified as HER2-positive (IHC 3 + or IHC 2+/FISH+) or HER2-low (IHC 1 + or IHC 2+/FISH-). Overall survival (OS) was the primary outcome and was evaluated using Kaplan-Meier and log-rank methods for unadjusted comparisons followed by multivariable Cox regression. A total of 111 patients were included (HER2-positive, n = 77; HER2-low, n = 34). HER2-low tumors were more often ER-positive than HER2-positive tumors (79.4% vs. 56.6%, respectively). Overall, 46.8% of patients had received ≥ 6 prior systemic therapy lines. In unadjusted analyses, greater prior chemotherapy exposure was associated with shorter OS (median OS not reached for 0 lines, 35.2 months for 1-2 lines, and 22.1 months for ≥ 3 lines). Median OS was longer in HER2-positive than HER2-low disease (35.2 vs. 12.8 months, respectively). In multivariable analysis, receipt of ≥ 3 prior chemotherapy lines was associated with shorter OS (aHR 9.95, 95% CI 1.20-82.53; p = 0.033), although this finding should be interpreted cautiously given the small sample size, wide confidence interval, and pooled analysis across HER2 subgroups. In this real-world cohort of patients with BCBM treated with T-DXd, HER2-positive disease was associated with longer unadjusted survival than HER2-low disease. Greater prior chemotherapy exposure may reflect poorer underlying prognosis and more heavily pretreated disease.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study
- Date Crossref
- 27/05/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Mount Sinai Medical Center pays non établi dans la noticeÉtablissement de santé
-
Baptist Hospital of Miami pays non établi dans la noticeÉtablissement de santé
-
Baptist Health South Florida pays non établi dans la noticeÉtablissement de santé
-
Dartmouth–Hitchcock Medical Center pays non établi dans la noticeÉtablissement de santé
-
Research Network (United States) pays non établi dans la noticeEntreprise
-
Florida International University pays non établi dans la noticeUniversité ou école supérieure
-
Miami Cancer Institute pays non établi dans la noticeStructure de recherche
-
Dartmouth Hitchcock Medical Center and Clinics pays non établi dans la noticeÉtablissement de santé
-
Guardian Research Network pays non établi dans la noticeInstitution
-
Herbert Wertheim College of Medicine pays non établi dans la noticeUniversité ou école supérieure
Mount Sinai Medical Center, Baptist Hospital of Miami et Baptist Health South Florida, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.